Pharmaceutical - UCB

Filter

Current filters:

UCB

Popular Filters

1 to 25 of 64 results

EMA’s PRAC recommends new measures to minimize known heart risks of hydroxyzine-containing medicines

13-02-2015

The European Medicines agency’s Pharmacovigilance Risk Assessment Committee (PRAC) has completed a…

EuropeHydroxyzinePharmaceuticalRegulationRespiratory and PulmonaryUCB

UCB’s Phase III results for Neupro will back filing in China this year

UCB’s Phase III results for Neupro will back filing in China this year

05-02-2015

Belgian drugmaker UCB has announced positive top-line results from two Phase III studies of Neupro (rotigotine…

ChinaNeuproNeurologicalPharmaceuticalResearchUCB

US and EU regulatory filings for UCB’s antiepileptic brivaracetam

US and EU regulatory filings for UCB’s antiepileptic brivaracetam

21-01-2015

Belgium’s largest pharma company UCB today announced regulatory filings in the USA and the European…

BRIVARACETAMEuropeNeurologicalPharmaceuticalRegulationUCBUSA

UCB signs up to $480 million global collaboration with Neuropore on PD

18-01-2015

Neuropore Therapies, a wholly-owned US subsidiary of Austria’s Ever Neuro Pharma, has entered into…

Ever Neuro PharmaGlobalLicensingNeurologicalNeuropore TherapiesNPT200-11PharmaceuticalResearchUCB

UCB appoints Jean-Christophe Tellier as chief executive

UCB appoints Jean-Christophe Tellier as chief executive

13-01-2015

Belgian drugmaker UCB has replaced chief executive Roch Doliveux with Jean-Christophe Tellier.

BelgiumBoardroomJean-Christophe TellierPharmaceuticalUCB

Sustained improvements for spondyloarthritis patients provided by Cimzia

22-12-2014

New data from the RAPID-axSpS study showed that the rapid improvements in clinical outcomes observed…

Anti-Arthritics/RheumaticsCimziaPharmaceuticalResearchUCB

Latest Ph III data for UCB’s brivaracetam presented at AES

Latest Ph III data for UCB’s brivaracetam presented at AES

08-12-2014

Positive primary efficacy and safety data from the latest Phase III study evaluating Belgian drugmaker…

BRIVARACETAMNeurologicalPharmaceuticalResearchUCB

Daiichi Sankyo and UCB sign agreement for Vimpat in Japan

Daiichi Sankyo and UCB sign agreement for Vimpat in Japan

28-11-2014

Japanese drug major Daiichi Sankyo and Belgian drugmaker UCB have entered into an agreement to jointly…

Daiichi SankyoJapanlacosamide Tablet and InjectionLicensingNeurologicalPharmaceuticalUCBVimpat

UCB calls upon UK government for greater incentives for industry partnering

UCB calls upon UK government for greater incentives for industry partnering

29-10-2014

Belgian drugmaker UCB has called for further collaboration in life sciences to enhance drug discovery…

PharmaceuticalResearchUCBUKUnited Kingdom

UCB launches awareness campaign for non-motor symptoms of Parkinson's disease

UCB launches awareness campaign for non-motor symptoms of Parkinson's disease

30-09-2014

Belgian drugmaker UCB has launched an awareness-raising campaign around brain-related illnesses such…

EuropeNeurologicalPharmaceuticalSocial IssuesUCB

FDA backs added use for UCB’s Vimpat

01-09-2014

Belgium’s largest drugmaker UCB said today that the US Food and Drug Administration has approved a…

NeurologicalPharmaceuticalRegulationUCBUSAVimpat

UCB expands access to clinical trial data

UCB expands access to clinical trial data

01-08-2014

Belgian drugmaker UCB is now part of the Multi-Sponsor Environment, allowing for the responsible sharing…

BelgiumClinical researchPharmaceuticalResearchUCB

UCB reports solid 1st-half performance

UCB reports solid 1st-half performance

31-07-2014

Belgian drugmaker UCB posted first-half 2014 revenue of 1.76 billion euros ($2.36 billion), plus 6%,…

BelgiumChemistryChief executiveEURFinancialOrganic chemistryPharmaceuticalUCBVimpat

UCB reports positive Phase III results for brivaracetam in epilepsy

UCB reports positive Phase III results for brivaracetam in epilepsy

23-07-2014

Belgian drugmaker UCB says its Phase III study of brivaracetam has shown the drug reduced partial-onset…

BelgiumBRIVARACETAMEpilepsyNeurologicalPartial-onset seizurePharmaceuticalResearchUCB

Seven pharma companies offer up compounds to UK researchers

Seven pharma companies offer up compounds to UK researchers

22-07-2014

UK researchers will be granted access to a ‘virtual library’ of deprioritized pharmaceutical compounds…

AstraZenecaEli LillyGlaxoSmithKlineJanssenMedical Research CouncilPfizerPharmaceuticalResearchTakeda PharmaceuticalUCBUK

UCB and Dermira link up for Cimzia in dermatology

UCB and Dermira link up for Cimzia in dermatology

03-07-2014

Belgium’s largest drugmaker UCB and Dermira, a privately held USA-based dermatology company, have entered…

CanadaCimziaDermatologicalsDermiraEuropeLicensingPharmaceuticalResearchUCBUSA

EIB and UCB partner to accelerate development of new medicines

EIB and UCB partner to accelerate development of new medicines

17-06-2014

The European Investment Bank (EIB), the financing institution of the European Union, has signed an agreement…

EuropeFinancialPharmaceuticalResearchUCB

UCB celebrates 10 years of investment in the UK since acquiring Celltech

UCB celebrates 10 years of investment in the UK since acquiring Celltech

02-06-2014

Belgian drugmaker UCB is today celebrating 10 years presence in the UK, following the company’s acquisition…

Business FinanceCelltechPharmaceuticalPharmaceutical sciencesUCBUK

UCB enters strategic alliance with Weill-Cornell in three discovery projects

03-04-2014

Belgian drugmaker UCB has launched a major, three-year strategic research alliance with Weill-Cornell…

MetabolicsPharmaceuticalRare diseasesResearchUCB

Global epilepsy market to reach $4.5 billion by 2019

Global epilepsy market to reach $4.5 billion by 2019

13-03-2014

The epilepsy therapeutics market value in the eight major countries - the USA, Canada, France, Germany,…

EisaiFycompaGlaxoSmithKlineGlobalMarkets & MarketingNeurologicalPharmaceuticalTrobaltUCBVimpat

Sanofi and UCB in immune-mediated diseases research partnership

Sanofi and UCB in immune-mediated diseases research partnership

11-03-2014

French pharma major Sanofi and UCB, Belgium’s largest drugmaker, have entered into a scientific and…

Anti-Arthritics/RheumaticsGastro-intestinalsImmunologicalsPharmaceuticalResearchSanofiUCB

1 to 25 of 64 results

COMPANY SPOTLIGHT

Menarini

Back to top